Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...

Immorta Bio Inc., a scientific longevity company dedicated to Treating Diseases of Aging and Treating Aging as Disease™, today announced new data demonstrating that its combination therapy of SenoVax™ ...

Coya is currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS ( ...

Researchers have found in a new study that in non-diabetic patients with advanced chronic kidney disease, combined therapy ...

Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of ...

Researchers in China report that a simple heart ultrasound measure of left ventricular underfilling is a valuable prognostic ...

Athlon Sports and ShopHQ are both owned by the same parent company. Featured products are selected independently by the ...

What ultimately separates Qi4D is how clearly the lineup is segmented. Tour models prioritize launch control and shot-shaping ...

China’s urban population surpassed 943m in 2024, say official statistics, an increase of 100m in just seven years. The ...

Despite the immense amount of genetic material present in each cell, around three billion base pairs in humans, this material ...

Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry ...

The CEO of Deep Green said it would be the first data center in the U.S. built to recycle the heat it generates into a ...